[Pleural effusion and pulmonary hypertension in a patient with Parkinson disease treated with cabergoline].
Cabergoline is a synthetic dopamine agonist used to treat Parkinson disease. The drug occasionally induces pleuropulmonary adverse effects, which manifest as pleural thickening or effusion, interstitial pneumonitis, pulmonary infiltrates, or fibrosis. We report a rare case of pleural effusion and severe pulmonary hypertension in a 79-year-old man with Parkinson disease who had been treated with cabergoline for 1 year. The symptoms disappeared 10 months after the drug was discontinued.
Haro-Estarriol
Manuel
M
Servicio de Neumología, Hospital Universitario de Girona Doctor Josep Trueta, Girona, España. mharo.girona.ics@gencat.cat
Sabater-Talaverano
Gladis
G
Rodríguez-Jerez
Francisco
F
Obrador-Lagares
Anton
A
Genís-Batlle
David
D
Sendra-Salillas
Salvi
S
D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects*; D000077465:Cabergoline; D004873:Ergolines / Q000009:adverse effects*; D006801:Humans; D006976:Hypertension, Pulmonary / Q000139:chemically induced*; D008297:Male; D010300:Parkinson Disease / Q000188:drug therapy*; D010996:Pleural Effusion / Q000139:chemically induced*
D000978:Antiparkinson Agents; D004873:Ergolines; D000077465:Cabergoline